Top-10 Global Pharma Reduces Regulatory Submission Drafting Time by 75%+ with IBM Multi-Agent AI

Authoring regulatory submissions requires highly skilled medical writers to synthesize complex trial protocols, participant data, and outcomes across text, tables, and charts — a slow and inconsistent process. Accelerating the pace from database lock to regulatory submission is critical for competitive first-to-market positioning and patient access.

IBM Consulting deployed a multi-agent generative AI system built on Microsoft Azure AI Studio and the AutoGen framework. A series of specialized AI agents act as digital workers — each expert in a specific authoring step — collaborating to draft clinical document sections with mutual verification, hallucination mitigation, and full audit traceability. Human-in-the-loop checkpoints are embedded throughout for review and approval.

The accelerator generates a 75–90% complete first draft of regulatory documents in minutes rather than multiple hours. Turnaround time from last patient visit to regulatory submission was accelerated by up to 75%. The system has been deployed in production within top-10 global pharma, delivering GxP-validated, enterprise-scale transformation.

• Multi-agent architectures with mutual verification are essential for hallucination mitigation in regulatory content, where every claim must be traceable to clinical evidence
• Embedding human-in-the-loop review breaks at defined stages preserves compliance with regulatory explainability requirements
• Fine-tuning agents on organization-specific data (ICH guidelines, prior submissions, regulator feedback) significantly improves first-draft quality and consistency